We are live on ! Find out more
ASBPW

Aspire Biopharma Warrant
ASBPW

36 hedge funds and large institutions have $2.94M invested in Aspire Biopharma Warrant in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 36 → 36 (0)

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

33% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 6

60% less capital invested

Capital invested by funds: $7.27M → $2.94M (-$4.33M)

Holders
36
Holders Change
–
Holders Change %
0%
% of All Funds
0.62%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
4
Reduced
6
Closed
5
Calls
$2.09M
Puts
–
Net Calls
+$2.09M
Net Calls Change
-$4K

Top Buyers

Rank Fund Capital Flow
1
PC
Periscope Capital
Ontario, Canada
+$83K
2
MF
Magnetar Financial
Illinois
+$26K
3
CS
Clear Street
New York
+$19.4K
4
BCM
Basso Capital Management
Connecticut
+$7.34K
5
ACM
Atalaya Capital Management
New York
+$7.28K

Top Sellers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
-$17K
2
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$12K
3
WAM
Weiss Asset Management
Massachusetts
-$8K
4
PCM
Prelude Capital Management
New York
-$4K
5
UBS Group
UBS Group
Switzerland
-$3.64K
Name Holding Trade Value Shares
Change 		Change in
Stake
CCM
26
CAAS Capital Management
New York
$8K – – –
DCM
27
Difesa Capital Management
New York
$8K – – –
BCM
28
Basso Capital Management
Connecticut
$6K +$7.34K +50,400 New
SFM
29
Spartan Fund Management
Canada
$5K +$6.49K +44,594 New
KKRC
30
Kohlberg Kravis Roberts & Co
New York
$3K -$1.78K -12,227 -33%
CH
31
CVI Holdings
Delaware
$3K – – –
MTCM
32
Mint Tower Capital Management
Netherlands
$3K – – –
PI
33
PEAK6 Investments
Illinois
$1K -$1.82K -12,500 -50%
BI
34
Bulldog Investors
New Jersey
$1K +$1.82K +12,500 New
COPPSERS
35
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$1K +$1.82K +12,500 New
WP
36
Woodline Partners
California
– -$17K -100,000 Closed
Hudson Bay Capital Management
37
Hudson Bay Capital Management
Connecticut
– -$12K -97,474 Closed
WAM
38
Weiss Asset Management
Massachusetts
– -$8K -66,199 Closed
UBS Group
39
UBS Group
Switzerland
– -$3.64K -24,995 -100%
PCM
40
Prelude Capital Management
New York
– -$4K -23,571 Closed
CM
41
Cohanzick Management
New York
– -$3K -18,383 Closed
1
2

ASBPW Hedge Fund Activity: Q3 2022 in Review

36 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma Warrant (ASBPW) for Q3 2022, worth a combined $2.94M — down 60% from $7.27M a quarter earlier.

Fund positioning in ASBPW was balanced in Q3 2022: 5 funds opened new positions, 5 closed out, 4 added to existing stakes and 6 trimmed.

The largest buyer was Periscope Capital, adding an estimated $83K. The largest seller was Woodline Partners, exiting entirely with an estimated $17K sold.

  • 36 institutional investors held Aspire Biopharma Warrant (ASBPW) as of Q3 2022, unchanged from Q2 2022.
  • Funds reported $2.94M of Aspire Biopharma Warrant stock for Q3 2022, down 60% quarter-over-quarter.
  • 5 funds opened new Aspire Biopharma Warrant positions in Q3 2022 and 5 closed out, a net change of 0 holders.
  • The largest Aspire Biopharma Warrant buyer in Q3 2022 was Periscope Capital, an estimated $83K added.
  • The largest Aspire Biopharma Warrant seller in Q3 2022 was Woodline Partners, an estimated $17K sold.

Based on aggregated 13F filings for Q3 2022.